JP2024541944A - スピロ三環ｒｉｐｋ１阻害薬及びその使用方法 - Google Patents
スピロ三環ｒｉｐｋ１阻害薬及びその使用方法 Download PDFInfo
- Publication number
- JP2024541944A JP2024541944A JP2024525060A JP2024525060A JP2024541944A JP 2024541944 A JP2024541944 A JP 2024541944A JP 2024525060 A JP2024525060 A JP 2024525060A JP 2024525060 A JP2024525060 A JP 2024525060A JP 2024541944 A JP2024541944 A JP 2024541944A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heteroaryl
- pharma
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272276P | 2021-10-27 | 2021-10-27 | |
| US63/272,276 | 2021-10-27 | ||
| US202263407851P | 2022-09-19 | 2022-09-19 | |
| US63/407,851 | 2022-09-19 | ||
| PCT/US2022/047657 WO2023076218A1 (en) | 2021-10-27 | 2022-10-25 | Spirotricycle ripk1 inhibitors and methods of uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024541944A true JP2024541944A (ja) | 2024-11-13 |
| JP2024541944A5 JP2024541944A5 (https=) | 2025-10-29 |
| JPWO2023076218A5 JPWO2023076218A5 (https=) | 2025-10-29 |
Family
ID=84364239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525060A Pending JP2024541944A (ja) | 2021-10-27 | 2022-10-25 | スピロ三環ｒｉｐｋ１阻害薬及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12180226B2 (https=) |
| EP (1) | EP4423096A1 (https=) |
| JP (1) | JP2024541944A (https=) |
| KR (1) | KR20240089062A (https=) |
| AU (1) | AU2022379477A1 (https=) |
| CA (1) | CA3236550A1 (https=) |
| MX (1) | MX2024005063A (https=) |
| TW (1) | TW202334166A (https=) |
| WO (1) | WO2023076218A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202523301A (zh) * | 2023-11-02 | 2025-06-16 | 美商默沙東有限責任公司 | Ripk1抑制劑及使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220636T1 (hr) * | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
-
2022
- 2022-10-25 EP EP22813786.5A patent/EP4423096A1/en active Pending
- 2022-10-25 WO PCT/US2022/047657 patent/WO2023076218A1/en not_active Ceased
- 2022-10-25 AU AU2022379477A patent/AU2022379477A1/en active Pending
- 2022-10-25 CA CA3236550A patent/CA3236550A1/en active Pending
- 2022-10-25 KR KR1020247013686A patent/KR20240089062A/ko active Pending
- 2022-10-25 JP JP2024525060A patent/JP2024541944A/ja active Pending
- 2022-10-25 US US18/049,344 patent/US12180226B2/en active Active
- 2022-10-25 TW TW111140443A patent/TW202334166A/zh unknown
- 2022-10-25 MX MX2024005063A patent/MX2024005063A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202334166A (zh) | 2023-09-01 |
| EP4423096A1 (en) | 2024-09-04 |
| AU2022379477A1 (en) | 2024-05-02 |
| US12180226B2 (en) | 2024-12-31 |
| MX2024005063A (es) | 2024-05-13 |
| WO2023076218A1 (en) | 2023-05-04 |
| KR20240089062A (ko) | 2024-06-20 |
| CA3236550A1 (en) | 2023-05-04 |
| US20230159558A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7592784B2 (ja) | Ｊａｋ１阻害剤としてのピペリジン－４－イルアゼチジン誘導体 | |
| JP7041198B2 (ja) | Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| US12319671B2 (en) | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | |
| US20240034731A1 (en) | Aza-quinazoline compounds and methods of use | |
| US20240092761A1 (en) | Quinazoline compounds and methods of use | |
| EP4329766A1 (en) | Ripk1 inhibitors and methods of use | |
| CN117083272A (zh) | 调节nlrp3的4-烷氧基-6-氧代-哒嗪衍生物 | |
| JP2024541944A (ja) | スピロ三環ｒｉｐｋ１阻害薬及びその使用方法 | |
| WO2023076133A1 (en) | Spirotricycle ripk1 inhibitors and methods of uses thereof | |
| EP4305040A1 (en) | Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors | |
| JP7680639B1 (ja) | Ｒｉｐｋ１阻害剤及び使用方法 | |
| CN118488957A (zh) | 螺三环ripk1抑制剂及其使用方法 | |
| TW202523301A (zh) | Ripk1抑制劑及使用方法 | |
| JP2025061677A (ja) | Ｒｉｐｋ１阻害剤及び使用方法 | |
| US20250235456A1 (en) | Methods of use for aza-quinazoline compounds | |
| TW202208358A (zh) | 用於治療亨汀頓舞蹈症之htt調節劑 | |
| WO2025253326A1 (ko) | Kras 저해제로서 신규한 3환 화합물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251021 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251021 |